Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases?

Annals of Surgery

Volumn 240, Issue 6, 2004, Pages 1052-1064

  Adam, René ^a   Pascal, Gerard ^a   Castaing, Denis ^a   Azoulay, Daniel ^a   Delvart, Valerie ^a   Paule, Bernard ^a   Levi, Francis ^a   Bismuth, Henri ^a   Margreiter, ^b   Jaeck, ^b   Senninger, ^b   Neuhaus, ^b   Clavien, ^b  

^a HÔPITAL PAUL BROUSSE   (France)

^b Hopital Paul Brousse 14 ^*

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TUMOR ANTIGEN;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 9744226672     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000145964.08365.01     Document Type: Conference Paper

References (32)

1. Stangl R, Altendorf-Hofmann A, Charnley RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343: 1405-1410.
2. Hughes KS, Simon R, Soughorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery. 1988;103:278-288.
3. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection based on 1588 patients. Assoc Fr Chirurgie Cancer. 1996;77:1254-1262.
4. Scheele J, Strangl R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
5. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
6. Adam R, Pascal G, Azoulay D, et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg. 2003;238:871-883.
7. Cady B, Jenkins RL, Steele GD Jr, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg. 1998;227:566-571.
8. Scheele J, Stangl R, Altendorf-Hofmann A, et al. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13-29.
9. Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg, 1986;73:727-731.
10. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999.
11. Registry of Hepatic Metastases. Resection of the liver for colorectal carcinoma metastases: a multiinstitutional study of indications for resection. Surgery. 1988;103:278-288.
12. Bakalakos EA, Kim JA, Young DC, et al. Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg. 1998;22:399-404.
13. Levi F, Zidani R, Brienza S, et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma: International Organization for Cancer Chronotherapy. Cancer. 1999;85:2532-2540.
14. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
15. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-147.
16. Rougier P, Van Cutsem E, Bajetta E, et al. Randomized trial of irinotecan vs fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;35:1407-1412.
17. Douillard J-Y, Cunningham D, Roth AD. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000;355:1041-1047.
18. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-522.
19. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal liver metastases. Ann Surg Oncol. 2001;8:347-353.
20. Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003;90:963-969.
21. World Health Organization. Handbook for Reporting Results of Cancer Treatment [WHO Offset Publication No. 48]. Geneva: World Health Organization, 1979.
22. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Ann Surg. 1989;210:127-138.
23. Weber SM, Jarnagin WR, DeMatteo RP, et al. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol. 2000;7:643-650.
24. Adam R. The importance of visceral metastasectomy in colorectal cancer. Ann Oncol. 2000;11:29-36.
25. Figueras J, Valls C, Rafecas A, et al. Resection rate and effect of chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg. 2001;88:980-985.
26. Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study [Abstract]. Proc Am Soc Clin Oncol. 2001;20:494.
27. Hobday TJ, Kugler JW, Mahoney MR, et al. Long term survivors of metastatic colorectal cancer treated with chemotherapy only: a North Central Cancer Treatment Group review. J Clin Oncol. 2002;20:4574-4580.
28. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002;86:1041-1046.
29. Tabira Y, Yasunaga M, Sakaguchi T, et al. Predicting initial recurrence pattern of esophageal cancer after neoadjuvant chemotherapy. Hepato-Gastroenterology. 2000;47:1315-1318.
30. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19:3203-3209.
31. Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial Lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997;226: 688-703.
32. Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109-117.